Document/ExhibitDescriptionPagesSize 1: 8-K Current Report HTML 36K
2: EX-99.1 Miscellaneous Exhibit HTML 11K
6: R1 Cover HTML 45K
9: XML IDEA XML File -- Filing Summary XML 11K
7: XML XBRL Instance -- aort-20220926_htm XML 21K
8: EXCEL IDEA Workbook of Financial Reports XLSX 8K
4: EX-101.LAB XBRL Labels -- aort-20220926_lab XML 67K
5: EX-101.PRE XBRL Presentations -- aort-20220926_pre XML 33K
3: EX-101.SCH XBRL Schema -- aort-20220926 XSD 10K
10: JSON XBRL Instance as JSON Data -- MetaLinks 11± 16K
11: ZIP XBRL Zipped Folder -- 0000784199-22-000174-xbrl Zip 19K
(Former name or former address, if changed since last report)
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
iCommon
Stock, $0.01 par value
iAORT
iNYSE
___________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions (see General Instruction A.2. below):
i☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
i☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
i☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
i☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company i☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers
On September 26, 2022, the Board of Directors (the “Board”) of Artivion, Inc., a Delaware corporation (the “Company”), increased the size of the Board to nine directors and appointed Elizabeth A. Hoff as a director and a member of the Compliance Committee of the Board, effective October 1, 2022.
Ms. Hoff has over 30 years of U.S. and international experience in the medical device industry. The Board appointed Ms. Hoff to serve as a director based on the entirety of her experience and skills, including her extensive leadership and business experience across public and private companies.
The Board has affirmatively determined
that Ms. Hoff qualifies as an independent director under the categorical standards of the corporate governance rules of the New York Stock Exchange and as defined under applicable law.
In connection with her appointment to the Board, Ms. Hoff will receive the same equity and cash compensation for director service as the Company provides to other non-employee directors, which is disclosed in the Company’s definitive proxy statement filed April 4, 2022.
There are no transactions, or proposed transactions, to which the Company
is or was a party and in which Ms. Hoff had a direct or indirect material interest that are required to be disclosed under Item 404(a) of Regulation S-K.
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
*Furnished herewith, not filed.
-2-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, Artivion, Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
